Filgrastim biosimilar is under clinical development by Biosimilar Solutions and currently in Phase I for Febrile Neutropenia. According to GlobalData, Phase I drugs for Febrile Neutropenia have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Filgrastim biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Filgrastim biosimilar overview
filgrastim biosimilar (BSC-1020) is under development for the treatment of severe chronic neutropenia, febrile neutropenia and chemotherapy induced neutropenia. It is administered through subcutaneous route. The drug candidate acts by targeting granulocyte colony-stimulating factor (G-CSF) receptor.
Biosimilar Solutions overview
Biosimilar Solutions (Biosimilar) is a company that provide biologic medicines to improve the life of patients. The company is headquartered in United States.
For a complete picture of Filgrastim biosimilar’s drug-specific PTSR and LoA scores, buy the report here.